Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer

Expert Rev Anticancer Ther. 2015;15(8):875-84. doi: 10.1586/14737140.2015.1069186.


Non-small lung cancer (NSCLC) is a lethal malignancy when diagnosed in advanced stage. The evolution of chemotherapy and the development of agents targeting certain molecular pathways involved in tumor progression improved the prognosis. Nintedanib is a new tyrosine kinase inhibitor, which exerts its activity by blocking VEGF, FGF and PDGF receptors and inhibits the angiogenic signaling by preventing receptor dimerization. Several Phase I and II studies proved its safety and efficacy in diverse solid tumors. In patients with advanced NSCLC, the administration of nintedanib may offer an additional chemotherapy benefit in terms of response rate, progression-free survival and overall survival particularly in patients with adenocarcinoma histology, with manageable toxicity. Here, we present an analytical review of literature regarding nintedanib and we focus on its particular importance in NSCLC treatment.

Keywords: adenocarcinoma; angiogenesis; nintedanib; non-small-cell lung cancer; tyrosine kinase inhibitor.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Disease-Free Survival
  • Docetaxel
  • Humans
  • Indoles / administration & dosage
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Molecular Targeted Therapy
  • Prognosis
  • Survival Rate
  • Taxoids / administration & dosage


  • Indoles
  • Taxoids
  • Docetaxel
  • nintedanib